Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01420952 · ClinicalTrials.gov registry record · Phase 1
Imaging of Brain Receptors Using (11C)mGlu1
A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01420952: Clinical Trial Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
NCT01420952 is a Phase 1 study that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01420952, a Phase 1 study, was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Background: \- (11C)mGlu1 is a new drug that helps to show where a protein, mGluR1, is found in the brain. The drug contains a small amount of radioactivity that can be detected by imaging studies like positron emission tomography (PET) scans. By looking at the mGluR1 receptors, researchers hope to better understand how they are involved in general health, brain disorders, and addiction. Objectives: * To test how (11C)mGlu1 is distributed in the brain and body. * To measure how mGluR1 receptors display (11C)mGlu1 during imaging studies. Eligibility: \- Healthy volunteers between 18 and 50 years of age. Design: * Participants will be screened with a medical history, physical exam, and blood and urine tests. This study requires four visits to the NIH Clinical Center. * Participants will have an initial evaluation, a magnetic resonance imaging (MRI) scan, a PET scan, and a final blood sample after the PET scan, all at different visits. * The MRI and PET scans will focus on the brain. Participants will receive (11C)mGlu1, and have scans to see how it shows up in the brain. * Some participants will have whole body imaging studies to see how (11C)mGlu1 shows up in the body.
Interventions
- DRUG [11C]LY2428703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-07-29 |
| Est. Completion | 2012-11-27 |
| Phase | Phase 1 |
Why NCT01420952 stopped before completion
NCT01420952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which [11C]LY2428703 is the first listed.
NCT01420952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01420952 about?
NCT01420952 is a clinical study titled "Imaging of Brain Receptors Using (11C)mGlu1". Background: \- (11C)mGlu1 is a new drug that helps to show where a protein, mGluR1, is found in the brain. The drug contains a small amount of radioactivity that can be detected by imaging studies like positron emission tomography (PET) scans. By looking at the mGluR1 receptors, researchers hope to...
What is the current status of trial NCT01420952?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-07-29. Estimated completion is 2012-11-27.
What interventions are being tested in trial NCT01420952?
The interventions under investigation include: [11C]LY2428703 (DRUG).
Who is sponsoring clinical trial NCT01420952?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01420952's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI